Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
31
CRBP Quote, Financials, Valuation and Earnings
Last price:
$9.48
Seasonality move
:
47.36%
Day range:
$9.50 - $10.16
52-week range:
$4.64 - $20.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
70.76x
P/B ratio:
1.85x
Volume:
497.7K
Avg. volume:
606.4K
1-year change:
-35.68%
Market cap:
$170.3M
Revenue:
--
EPS (TTM):
-$5.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
-- | -$1.71 | -- | -103.83% | $42.33 |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 144.6% | -70.59% | $12.33 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.4M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
CRIS
Curis, Inc.
|
$2.9M | -$0.60 | -2.86% | -65.51% | $14.00 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
$9.70 | $42.33 | $170.3M | -- | $0.00 | 0% | 70.76x |
|
AGEN
Agenus, Inc.
|
$3.79 | $12.33 | $128.9M | -- | $0.00 | 0% | 0.96x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$5.90 | $9.00 | $214.3M | -- | $0.00 | 0% | 48.94x |
|
CRIS
Curis, Inc.
|
$1.16 | $14.00 | $15M | -- | $0.00 | 0% | 1.11x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.79 | $11.00 | $144M | 25.76x | $0.00 | 0% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
2.18% | 3.012 | 1.29% | 6.11x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.715 | 164.57% | 0.11x |
|
CRIS
Curis, Inc.
|
192.35% | 3.282 | 144.76% | 0.62x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
-$100K | -$24.4M | -52.96% | -54.17% | -- | -$15.6M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Corbus Pharmaceuticals Holdings, Inc. vs. Competitors
-
Which has Higher Returns CRBP or AGEN?
Agenus, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -116.82%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About CRBP or AGEN?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 336.43%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 225.42%. Given that Corbus Pharmaceuticals Holdings, Inc. has higher upside potential than Agenus, Inc., analysts believe Corbus Pharmaceuticals Holdings, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 AGENAgenus, Inc.2 1 0 -
Is CRBP or AGEN More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.713, which suggesting that the stock is 171.268% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock CRBP or AGEN?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or AGEN?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 0.96x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M AGENAgenus, Inc.0.96x -- $30.2M $63.9M
-
Which has Higher Returns CRBP or AIM?
AIM ImmunoTech has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -10571.43%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About CRBP or AIM?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 336.43%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe AIM ImmunoTech is more attractive than Corbus Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 AIMAIM ImmunoTech1 0 0 -
Is CRBP or AIM More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.713, which suggesting that the stock is 171.268% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock CRBP or AIM?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or AIM?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns CRBP or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -2301.55%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About CRBP or ARMP?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 336.43%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 52.54%. Given that Corbus Pharmaceuticals Holdings, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Corbus Pharmaceuticals Holdings, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is CRBP or ARMP More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.713, which suggesting that the stock is 171.268% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.
-
Which is a Better Dividend Stock CRBP or ARMP?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or ARMP?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 48.94x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M ARMPArmata Pharmaceuticals, Inc.48.94x -- $1.2M -$26.7M
-
Which has Higher Returns CRBP or CRIS?
Curis, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -243.36%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About CRBP or CRIS?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 336.43%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1106.9%. Given that Curis, Inc. has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe Curis, Inc. is more attractive than Corbus Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 CRISCuris, Inc.4 0 0 -
Is CRBP or CRIS More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.713, which suggesting that the stock is 171.268% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.
-
Which is a Better Dividend Stock CRBP or CRIS?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or CRIS?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 1.11x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M CRISCuris, Inc.1.11x -- $3.2M -$7.7M
-
Which has Higher Returns CRBP or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of 13.19%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About CRBP or PLX?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 336.43%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 514.53%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Corbus Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is CRBP or PLX More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.713, which suggesting that the stock is 171.268% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock CRBP or PLX?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or PLX?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 2.28x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M PLXProtalix Biotherapeutics, Inc.2.28x 25.76x $17.9M $2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 3.51% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.79% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 5.81% over the past day.
